Indigenous rural communities in the tropics manage parasitic diseases, like malaria and leishmaniasis, using herbal drugs. The efficacy, dosage, safety and active principles of most of the herbal preparations are not known. Extracts from 6 selected plant species, used as medicinal plants by indigenous local communities in Kenya, were screened for in vitro anti-plasmodial and anti-leishmanial activity, against 2 laboratory-adapted Plasmodium falciparum isolates (D6, CQ-

The potential of Leishmania major culture-derived soluble exogenous antigens (SEAgs) to induce a protective response in susceptible BALB/c mice challenged with L. major promastigotes was investigated. Groups of BALB/c mice were immunized with L. major SEAgs alone, L. major SEAgs coadministered with either alum (aluminum hydroxide gel) or recombinant murine interleukin-12 (rmIL-12), L. major SEAgs coadministered with both alum and rmIL-12, and L. major SEAgs coadministered with Montanide ISA 720. Importantly and surprisingly, the greatest and most consistent protection against challenge with L. major was seen in mice immunized with L. major SEAgs alone, in the absence of any adjuvant. Mice immunized with L. major SEAgs had significantly smaller lesions that at times contained more than 100-fold fewer parasites. When lymphoid cells from L. major SEAg-immunized mice were stimulated with leishmanial antigen in vitro, they proliferated and secreted a mixed profile of type 1 and type 2 cytokines. Finally, analyses with Western blot analyses and antibodies against three surface-expressed and secreted molecules of L. major (lipophosphoglycan, gp46/M2/ PSA-2, and gp63) revealed that two of these molecules are present in L. major SEAgs, lipophosphoglycan and the molecules that associate with it and gp46/M2/PSA-2.

Leishmania spp are protozoan parasites of the Trypanosomatidae family that cause disease in humans and animals. In general, infections with these parasites can be divided into three main forms namely, cutaneous, mucocutaneous, and visceral leishmaniases. The disease is prevalent in many tropical and subtropical regions of the world, where it is transmitted via the bite of an infected sand fly. Leishmaniasis has been known to be endemic in parts of Kenya from as far back as early in the 20 th century. These endemic areas include Turkana, Baringo, Kitui, Machakos, Meru, West Pokot and Elgeyo Marakwet districts which have been reported to be endemic for kala-azar. Recent outbreaks of VL have been reported in the previously non-endemic districts of Wajir and Mandera in North Eastern Kenya between May 2000 and August 2001. The vector for VL in Kenya is Phlebotomus martini though other vectors including P. orientalis have been reported. Baringo district is the only foci reported where both VL and CL are known to occur in Kenya. The aetiological agents for CL which include L. majo r which has been reported in Baringo; L. tropica in Laikipia, Samburu, Isiolo, Nakuru and Nyandarua districts while L. aethiopica has been reported in the Mt Elgon area. In Kenya, P. duboscqi, P. guggisbergi have been shown to be the vectors of L. major and L. tropica, respectively, while P. pediffer, P. longipes and P. elgonensis have been implicated as vectors of L. aethiopica. Since 1980, the Kenya Medical Research Institute (KEMRI) has spearheaded research on leishmaniases research in Kenya focusing on various aspects including characterization of Leishmania species, biology, and ecology of sand fly vectors, development of biological strategies for sand fly control, identification of animal reservoirs, diagnosis, new treatment strategies, new chemotherapeutic agents, and vaccine-related studies. KEMRI, a founding partner of the Drugs for Neglected Disease Initiative (DNDi), whose overall aim is to address lack of new or improved drugs for neglected diseases (which include leishmaniases, malaria, trypanosomiasis and chagas disease) has made major contributions in leishmaniases research and control in Kenya and the eastern Africa region.

The increased global demand for improved disease detection and control has resulted in the expansion of diagnostic and research capacity. However, the increase in infectious disease detection capacity has not necessarily been paralleled by an increase in biosafety and biosecurity capacity, particularly in low-resource countries. Low-resource countries face numerous challenges that severely constrain the development, or expansion, of sustainable capacity in biosafety and biosecurity management. This article divides these challenges into nine broad categories: 1) Country-/Regionspecific Regulatory Framework and Guidelines or Standards; 2) Biosafety Awareness; 3) Infrastructure; 4) Equipment, Reagents, and Services; 5) Management Processes and Administrative Controls; 6) Biosafety Curricula; 7) Training; 8) Biosafety Associations, Professional Competency, and Credentialing; and 9) Individual Mentoring and Organizational Twinning.Overcoming these challenges requires the collaborative efforts of representatives from the highest levels of local governments, the international biosafety community (e.g., international, regional, and national biosafety associations), and international development partners (e.g., national government agencies and programs, World Health Organization (WHO), World Bank, Food and Agriculture Organization of the United Nations (FAO), and the World Organization for Animal Health (OIE) to identify, fund, and execute solutions for sustainable capacity development. Collaboration is required to develop solutions appropriate for the specific needs and available resources within any given country.